Ticagrelor: Effects Beyond the P2Y12 Receptor.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Interventional Cardiology Clinics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.iccl.2016.08.004PMID 27886822
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.

  2016cited by this paper
• Dyspnea related to reversibly-binding P2Y12 inhibitors: A review of the pathophysiology, clinical presentation and diagnostics.

  2016cited by this paper
• P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction

  2015cited by this paper
• Dyspnoea management in acute coronary syndrome patients treated with ticagrelor

  2015cited by this paper
• The role of platelets in inflammation

  2015cited by this paper
• Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model

  2015cited by this paper
• A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2015cited by this paper
• Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes

  2014cited by this paper
• Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1

  2014cited by this paper
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.

  2014cited by this paper
• 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.

  2013cited by this paper
• Differential Effect of Ticagrelor Versus Prasugrel on Coronary Blood Flow Velocity in Patients With Non–ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Exploratory Study

  2013cited by this paper
• Ticagrelor Improves Peripheral Arterial Function in Patients with a Previous Acute Coronary Syndrome

  2013cited by this paper
• Tubuloglomerular feedback and renal function in mice with targeted deletion of the type 1 equilibrative nucleoside transporter.

  2013cited by this paper
• Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans.

  2013cited by this paper
• Cardiovascular adenosine receptors: expression, actions and interactions.

  2013cited by this paper
• Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study

  2013cited by this paper
• Regulation of Neutrophil Function by Adenosine

  2012cited by this paper
• Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.

  2012cited by this paper
• Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model

  2012cited by this paper
• Why does ticagrelor induce dyspnea?

  2012cited by this paper
• An emerging role for adenosine and its receptors in bone homeostasis

  2012cited by this paper
• Abstract 213: Ticagrelor Inhibits Human Platelet Aggregation via Adenosine in Addition to P2Y12 Antagonism

  2012cited by this paper
• Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.

  2012cited by this paper
• Physiological implications of adenosine receptor‐mediated platelet aggregation

  2011cited by this paper
• 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

  2011cited by this paper
• Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.

  2011cited by this paper
• The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy.

  2011cited by this paper
• Blockade of airway sensory nerves and dyspnea in humans.

  2010cited by this paper
• Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.

  2010cited by this paper
• Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.

  2010cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology.

  2009cited by this paper
• Nucleoside transporter proteins.

  2009cited by this paper
• Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study

  2009cited by this paper
• Platelet alpha-granules: basic biology and clinical correlates.

  2009cited by this paper
• Effects of airway anesthesia on dyspnea and ventilatory response to intravenous injection of adenosine in healthy human subjects.

  2008cited by this paper
• Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Biology and pharmacology of the platelet P2Y12 receptor.

  2006cited by this paper
• Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.

  2006cited by this paper
• Protease-Activated Receptors in Cardiovascular Diseases

  2006cited by this paper
• Clopidogrel Improves Systemic Endothelial Nitric Oxide Bioavailability in Patients With Coronary Artery Disease: Evidence for Antioxidant and Antiinflammatory Effects

  2006cited by this paper
• Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease.

  2005cited by this paper
• Adenosine Augments IL-10 Production by Macrophages through an A2B Receptor-Mediated Posttranscriptional Mechanism1

  2005cited by this paper
• Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.

  2004cited by this paper
• Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.

  2004cited by this paper
• Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection.

  2001cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Activated platelets and endothelial cell interaction with neutrophils under flow conditions.

  2001cited by this paper
• Pharmacokinetics of clopidogrel.

  1999cited by this paper
• Platelet/Polymorphonuclear Leukocyte Interaction: P-Selectin Triggers Protein-Tyrosine Phosphorylation–Dependent CD11b/CD18 Adhesion: Role of PSGL-1 as a Signaling Molecule

  1999cited by this paper
• Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule.

  1999cited by this paper
• Protease-Activated Receptors and Platelet Function

  1999cited by this paper
• Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes

  1995cited by this paper
• Transport and metabolism of adenosine in human erthrocytes: Effect of transport inhibitors and regulation by phosphate

  1986cited by this paper

• Differential effects of dual antiplatelet and dual antithrombotic therapy on hemostasis in chronic coronary syndrome patients: the DEFINE CCS study

  2025cites this paper
• Comparison of Ticagrelor with Clopidogrel on Coronary Microvascular Dysfunction Following Acute Myocardial Infarction Using Angiography-Derived Index of Microcirculatory Resistance

  2024cites this paper
• Translational Experimental Basis of Indirect Adenosine Receptor Agonist Stimulation for Bone Regeneration: A Review

  2024cites this paper
• Disnea secundaria a ticagrelor posterior a arteriografía coronaria. Reporte de caso

  2022cites this paper
• Bimodal Effects of P2Y12 Antagonism on Matrix Metalloproteinase–Associated Contractile Dysfunction in İnsulin-Resistant Mammalian Heart

  2021cites this paper
• Use of ticagrelor and the risks of pneumonia and pneumonia-specific death in patients with non-acute coronary syndrome conditions: a population-based cohort study

  2021cites this paper
• Utility of P2Y12 reactive unit (PRU) assessment on ticagrelor in cerebral aneurysms treated with intracranial stenting and flow diversion: Cohort study and Case Report from 2 Neurovascular Centers.

  2020cites this paper
• Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development

  2020cites this paper
• The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel

  2020cites this paper
• Risk of infections in patients treated with ticagrelor versus clopidogrel: a systematic review and meta-analysis.

  2020cites this paper
• The Role of Current Major Antiplatelet Agents in Cardiovascular Diseases

  2020cites this paper
• Inhibiting P2Y12 in Macrophages Induces Endoplasmic Reticulum Stress and Promotes an Anti-Tumoral Phenotype

  2020cites this paper
• Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel

  2019cites this paper
• Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel

  2019cites this paper
• Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF)

  2018cites this paper
• Effect of Potent P2Y12 Inhibitors on Ventricular Arrhythmias and Cardiac Dysfunction in Coronary Artery Disease: A Systematic Review and Meta-Analysis

  2018cites this paper
• Inflammatory vs. Thrombotic States of Platelets: A Mini-review with a Focus on Functional Dichotomy

  2018cites this paper
• The value of using polymorphisms in anti-platelet therapy

  2017cites this paper